Navigation Links
New Second Edition of Pharmaceutical Patent Law Examines Critical Intersection of Patent Law and Food and Drug Law
Date:1/3/2011

ARLINGTON, Va., Jan. 3, 2011 /PRNewswire-USNewswire/ -- BNA Books, a division of BNA, announces the publication of the Second Edition of Pharmaceutical Patent Law, the most relied upon reference available with a detailed, practitioner-oriented treatment of pharmaceutical patent law from the perspective of both patent law and the food and drug laws.

(Logo: http://photos.prnewswire.com/prnh/20090529/DC24463LOGO)

This revised treatise takes on the complicated tasks of tracking legal developments within the PTO, FDA, Congress, the courts, the FTC, the Department of Justice, and the WTO. This treatise examines how these agencies and organizations interact with each other and analyzes how they will impact strategies within a practitioner's core area of expertise.

Pharmaceutical Patent Law, Second Edition provides complete coverage of advanced topics, including the antitrust implications of patent settlements, the experimental use privilege, and international aspects of the field. Core topics covered include:

  • The substance and procedure of pharmaceutical patent acquisition
  • FDA marketing approval procedures for innovative and generic drugs
  • The FDA's Orange Book
  • Patent term extension standards
  • FDA marketing exclusivities
  • The scope of patent rights
  • Patent infringement procedures under the Hatch-Waxman Act
  • Defenses to patent infringement
  • Remedies for patent infringement
  • The experimental use privilege
  • Antitrust treatment of pharmaceutical patent settlements
  • International aspects of pharmaceutical patent practice

The Second Edition includes the following new information:

  • Extensive coverage of the new follow-on biologics statute
  • The impact of Bilski v. Kappos on diagnostic method claims
  • New judicial guidance on patent term extensions under the Hatch-Waxman Act
  • Significant case law regarding forfeiture of the 180-day generic exclusivity
  • The developing law of "obvious to try" in the post-KSR era

Pharmaceutical Patent Law, Second Edition not only reviews current issues of importance, but identifies topics such as parallel importation and authorized generics that are likely to be of growing significance. The author, Professor John R. Thomas, is a member of the faculty of Georgetown University Law Center, Washington, DC, where he teaches courses in both patent and food and drug law.

BNA is a leading private publisher of news and information products for professionals in law and business. In addition to Pharmaceutical Patent Law, BNA's Book Division publishes Anatomy of a Patent Case;  Biotechnology and the Federal Circuit; Constructing and Deconstructing Patents; Drafting Patent License Agreements; Electronic and Software Patents: Law and Practice; Intellectual Property Taxation: Transaction and Litigation Issues; International Patent Litigation: A Country-by-Country Analysis; Patent Infringement Remedies; Patent Law and Practice; Patent Prosecution: Law, Practice, and Procedure; Patent, Trademark, and Copyright Laws; Patent, Trademark, and Copyright Regulations; Patents and the Federal Circuit; Trademark Litigation Practice; Harmon on Patents: Black-Letter Law and Commentary; and other titles in legal specialties. The BNA Books website, including an online catalog, can be found at bnabooks.com.

The new Second Edition of Pharmaceutical Patent Law may be purchased (860 pp. Hardcover/Order #1898-PREL10/$445.00 plus tax, shipping, and handling) from BNA Books, PO Box 7814, Edison, NJ 08818-7814. Telephone orders: 1-800-960-1220. Fax orders: 1-732-346-1624. For a free BNA Books catalog, call 1-800-960-1220 or send an e-mail request to books@bna.com. A 10% discount is available on print copies of books when ordered from the website at bnabooks.com. (Please note that discounts cannot be combined).


'/>"/>
SOURCE BNA Books
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Spherix Reports Second Quarter Earnings
2. Tapestry Reports Second Quarter 2007 Results
3. Callisto Reports on Second-Quarter 2007 Milestones
4. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
11. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... 2016 Mundipharma EDO GmbH (Early ... first-in-human clinical trial of its investigational drug candidate EDO-S101. ... currently being developed for the treatment of relapsed-refractory (RR) ... evaluate the safety and tolerability of ascending doses of ... the United States and ...
(Date:5/31/2016)... AMSTERDAM , May 31, 2016 ... Share and Annotate Content From Elsevier,s ScienceDirect Database ... of scientific, technical and medical information products and ... Berlin -based scientific collaboration platform PaperHive to ... the over 12 million articles on ScienceDirect ...
(Date:5/31/2016)... , May 31, 2016 CollPlant Ltd. ... plant-based rhCollagen technology for tissue repair products - announces ... of Israel,s Ministry of Economy, ... development project for 2016. The Chief Scientist,s grant amount to ... grant, which totaled NIS 4.7 million.  The ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... ... mix of advanced Artificial Intelligence (AI) and the latest in Clinical Patient ... center is integrating predictive analytic outputs directly into the clinical workflow. These insights ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... diagnostics device that enables unprecedented portability and convenience. , The Cube is exceptionally ... cubed in size, the Cube fits easily into any space, whether in a ...
(Date:5/31/2016)... , ... May 31, 2016 , ... The Global ... today released ten predictions on the future of wellness, travel, spa and beauty in ... travel, spa and beauty companies to leading economists and researchers - to forecast where ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... The Orthopaedic ... executive committee members: , David G. Lewallen, MD, began his term as president ... president. Michael L. Parks, MD, is OREF’s new president-elect. Richard F. Kyle, MD, will ...
(Date:5/31/2016)... ... ... a recent interview on The Greenburgh Report radio show hosted by Greenburgh, NY Town ... leading medical insurance advocate Adria Goldman Gross discussed several eye-opening issues that have combined ... the interview with Mr. Feiner that aired on May 7, 2016, Ms. Gross, the ...
Breaking Medicine News(10 mins):